Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Pathological Features and Genetic Research on Gastrointestinal Cancer
share announcement

Pathological Features and Genetic Research on Gastrointestinal Cancer

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (15 November 2023) | Viewed by 1507

Special Issue Editors

Dr. Hsiangyao Shih

E-Mail Website
Guest Editor
Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
Interests: neurodegenerative disease; protein misfolding; nanoparticle targeted drug delivery; mitochondrial metabolism; ischemia reperfusion
Dr. Lin Han Chen

E-Mail Website
Guest Editor
Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
Interests: neurodegenerative disease; protein misfolding; nanoparticle targeted drug delivery; mitochondrial metabolism; ischemia reperfusion

Special Issue Information

Dear Colleagues,

Gastrointestinal (GI) cancers account for around a quarter of global cancer incidence and one-third of all cancer-related deaths. Although the recent progress in therapeutic and disease mechanisms has been uncovered, the mortality and societal impact of GI cancer is experienced worldwide. It is still one of the critical challenges of public health. Recently, new therapies within newly discovered molecular biology have been reported and successfully decreased the mortality of GI cancer, such as targeted therapy, immunotherapy, nanomedicine, and CRISPR/Cas9 therapeutics. To develop and translate these therapeutic methods into the clinic, the understanding of precise pathological features and genetic information is urgently needed.

Therefore, in the proposed Special Issue of Biomedicines, we want to recruit works covering therapies related to the latest molecular tools for GI cancer. We also welcome the submission of papers covering findings related to molecular biomarker and pathological features, which can help with the early diagnosis and prevention of GI cancer.

Dr. Hsiangyao Shih
Dr. Lin Han Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal (GI) cancers
  • genetic pathology
  • translational medicine
  • biomarkers
  • cancer therapeutics

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1123 KiB  
Article
Chronic Obstructive Pulmonary Disease Is Associated with Worse Oncologic Outcomes in Early-Stage Resected Pancreatic and Periampullary Cancers
by Rachel Huang, Emma Hammelef, Matthew Sabitsky, Carolyn Ream, Saed Khalilieh, Nitzan Zohar, Harish Lavu, Wilbur B. Bowne, Charles J. Yeo and Avinoam Nevler
Biomedicines 2023, 11(6), 1684; https://doi.org/10.3390/biomedicines11061684 - 10 Jun 2023
Viewed by 1175
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer mortality in the United States. Hypoxic and hypercapnic tumor microenvironments have been suggested to promote tumor aggressiveness. The objective of this study was to evaluate the association between chronic obstructive pulmonary disease [...] Read more.
Pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer mortality in the United States. Hypoxic and hypercapnic tumor microenvironments have been suggested to promote tumor aggressiveness. The objective of this study was to evaluate the association between chronic obstructive pulmonary disease (COPD) and oncologic survival outcomes in patients with early-stage PDAC and periampullary cancers. In this case-control study, patients who underwent a pancreaticoduodenectomy during 2014–2021 were assessed. Demographic, perioperative, histologic, and oncologic data were collected. A total of 503 PDAC and periampullary adenocarcinoma patients were identified, 257 males and 246 females, with a mean age of 68.1 (±9.8) years and a mean pre-operative BMI of 26.6 (±4.7) kg/m2. Fifty-two percent of patients (N = 262) reported a history of smoking. A total of 42 patients (8.3%) had COPD. The average resected tumor size was 2.9 ± 1.4 cm and 65% of the specimens (N = 329) were positive for lymph-node involvement. Kaplan–Meier analysis showed that COPD was associated with worse overall and disease-specific survival (p < 0.05). Cox regression analysis showed COPD to be an independent prognostic factor (HR = 1.5, 95% CI 1.0–2.3, p = 0.039) along with margin status, lymphovascular invasion, and perineural invasion (p < 0.05 each). A 1:3 nearest neighbor propensity score matching was also employed and revealed COPD to be an independent risk factor for overall and disease-specific survival (OR 1.8 and OR 1.6, respectively; p < 0.05 each). These findings may support the rationale posed by in vitro laboratory studies, suggesting an important impact of hypoxic and hypercapnic tumor respiratory microenvironments in promoting therapy resistance in cancer. Full article
(This article belongs to the Special Issue Pathological Features and Genetic Research on Gastrointestinal Cancer)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop